Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.
Fusen Pharmaceutical Company Limited has scheduled a board meeting for 31 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the possible declaration of a final dividend, a decision that could affect shareholder returns and signal management’s assessment of the group’s financial performance.
The meeting underscores the company’s adherence to Hong Kong listing requirements on timely financial disclosure, providing investors with clarity on its operating results and capital allocation plans. Confirmation of any dividend would be closely watched by shareholders as an indicator of cash flow strength and confidence in the company’s ongoing prospects.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.72 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited is a Hong Kong–listed pharmaceutical company incorporated in the Cayman Islands and traded on the Main Board of the Stock Exchange of Hong Kong under stock code 1652. The group operates through a number of subsidiaries and is engaged in the development, production and sale of pharmaceutical products for the healthcare market.
Average Trading Volume: 505,927
Technical Sentiment Signal: Buy
Current Market Cap: HK$992.6M
For an in-depth examination of 1652 stock, go to TipRanks’ Overview page.